EUVIMEDEUVIMED entdecken
Crossref

Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma

Hitesh Kumar, Pallavi Chand, Shantanu Pachal, Sahid Mallick, Rupshee Jain, SubbaRao V Madhunapantula iD, Vikas Jain iD

Molecular Pharmaceutics · 04.12.2023 · 20 (12) · 6035-6055

DOI: 10.1021/acs.molpharmaceut.3c00309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 31.10.2023. Verfasst von Hitesh Kumar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570015, India. Hauptthemen laut MEDLINE: Nanostructures, Melanoma. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Science and Engineering Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fisetin (Fis), a natural flavonoid with anticancer effects, suffers from delivery constraints. Fisetin-nanostructured lipid carriers (NLCs) were developed for better efficacy against metastatic melanoma, employing the design of experiment (DoE) approach. The optimized NLCs depict a particle diameter of 135.0 ± 5.5 nm, a polydispersity index (PDI) of 0.176 ± 0.035, and an entrapment efficiency of 78.16 ± 1.58%. The formulation was stable over a period of 60 days and demonstrated sustained release of the drug (74.79 ± 3.75%) over 96 h. Fis-NLCs depicted at least ∼3.2 times lower IC50 value and ∼1.8 times higher drug uptake at 48 h in A-375 and B16F10 cells compared to that of Fis. It also inhibited the mobility of melanoma cells and induced cell cycle arrest at the G1/S phase. Reverse transcriptase polymerase chain reaction (RT-PCR) and Western blot results show enhanced expression of Nrf2/NQO1 genes and an apoptotic effect by the upregulation of BAX mRNA expression. The protein levels of BAX and p53 were ∼2-fold higher compared with that of pure Fis. In-vivo studies demonstrated 5.9- and 10.7-fold higher inhibition in melanoma-associated metastasis in the lungs and liver, respectively. The outcomes from this study demonstrated Fis-NLCs as an effective tool against melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanostructuresMelanomaHumansDrug Carriersbcl-2-Associated X ProteinLipidsParticle SizeFlavonols

Stichwörter der Autor:innen

advanced melanomadesign of experimentfisetinflavonoidmelanomananostructured lipid carriers

Substanzen

Drug Carriersbcl-2-Associated X ProteinLipidsfisetinFlavonols

Autor:innen und Institutionen

  • Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570015, India.
  • Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570015, India.
  • Department of Biochemistry, Centre of Excellence in Molecular Biology & Regenerative Medicine, JSS Medical College, JSS Academy of Higher Education & Research, Mysuru 570015, India.

ORCID-Profile: SubbaRao V Madhunapantula, Vikas Jain

Förderung

  • Science and Engineering Research Board

Zitieren

APA

Kumar, H., Chand, P., Pachal, S., Mallick, S., Jain, R., Madhunapantula, S. V., & Jain, V. (2023). Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma. Molecular Pharmaceutics, 20(12), 6035-6055. https://doi.org/10.1021/acs.molpharmaceut.3c00309

Vancouver

Kumar H, Chand P, Pachal S, Mallick S, Jain R, Madhunapantula SV, et al. Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma. Molecular Pharmaceutics. 2023;20(12):6035-6055. doi:10.1021/acs.molpharmaceut.3c00309

BibTeX
@article{Kumar2023,
  author = {Kumar, Hitesh and Chand, Pallavi and Pachal, Shantanu and Mallick, Sahid and Jain, Rupshee and Madhunapantula, SubbaRao V and Jain, Vikas},
  title = {Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  volume = {20},
  number = {12},
  pages = {6035--6055},
  doi = {10.1021/acs.molpharmaceut.3c00309}
}
Kostenlos starten →